For the Inventor, By the Inventor

Enter assignee name

Marseille, France

Trophos

Calculating rank

USPTO Granted Patents = 15

% Expired Patents = 93.3

CIPO Patents = 6

EPO Patents = 7

Forward Citations = 15

Loading Chart...

Loading Chart...

15 inventors (with patents filed for the assignee):

Cyrille Drouot (9 out of 9 patents)

Thierry Bordet (7 out of 7 patents)

Bruno Buisson (6 out of 6 patents)

4. Rebecca Pruss (5 out of 5 patents)

5. Corinne Chaimbault (3 out of 3 patents)

6. Michel Delaage (3 out of 15 patents)

7. Pascal Villa (2 out of 2 patents)

8. Toni Williamson (2 out of 2 patents)

9. Laure Jamot (1 out of 3 patents)

10. Abdesslamc Nazih (1 out of 1 patent)

11. Cyrillo Drouot (1 out of 1 patent)

12. Abdesslame Nazih (1 out of 1 patent)

13. Céline Simon (1 out of 1 patent)

14. Delphine Maux (1 out of 1 patent)

15. Christopher Henderson (1 out of 2 patents)

15 patents: Sort by Forward Citations

1. 9447140 - Cholest-4-en-3-one oxime derivatives, pharmaceutical compositions containing same, and preparation method (2016-09-20),

2. 9320745 - Use of cholest-4-en-3-one derivatives for obtaining a cytoprotective drug (2016-04-26),

3. 9115059 - Oxime derivatives of 3,5-seco-4-nor-cholestane, pharmaceutical compositions containing same, and method for preparing same (2015-08-25),

4. 9045393 - Derivatives of 3.5-seco-4-norcholestane and use thereof (2015-06-02),

5. 8691854 - Chemical compounds and the uses thereof as a medicine (2014-04-08),

6. 8575138 - Method for providing neuroprotection (2013-11-05),

7. 8481515 - Derivatives of cholest-4-en-3-one oxime, pharmaceutical compositions containing them and preparation method (2013-07-09),

8. 8354395 - Method for providing neuroprotection from spinal muscular atrophy (2013-01-15),

9. 8338488 - Use of at least one oxime derivative of 3,5-seco-4-nor-cholestane as antioxidants (2012-12-25),

10. 8283341 - Use as medicaments of derivatives of cholest-4-en-3-one, pharmaceutical compositions containing them, novel derivatives and their preparation process (2012-10-09),

11. 7985774 - Use of 3,5-seco-4-nor-cholestane derivatives for obtaining a cytoprotective drug (2011-07-26),

12. 7858603 - Use of derivatives of cholest-4-en-3-one as medicaments, pharmaceutical compositions containing same, novel derivatives and preparation method thereof (2010-12-28),

13. 7372626 - Device for sequential observation of samples and methods using same (2008-05-13),

14. 7072105 - Device for positioning a plate used for analyzing samples on an examination device (2006-07-04),

15. 6949354 - Methods for screening compounds active on neurons (2005-09-27),

Company Overview

Trophos is a biotechnology company based in Marseille, France, specializing in the development of innovative therapies for neurodegenerative diseases. The organization focuses on harnessing its proprietary technology to create treatments that target mitochondrial dysfunction, a key factor in various neurological conditions. Trophos is dedicated to advancing research in the field of neurobiology, aiming to improve the quality of life for patients affected by these challenging disorders through cutting-edge scientific approaches.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Nov 3 2026

15 Patents

#9 in Marseille

#1,262 in France

#40,021 in the World

Marseille, France

Trophos

Forward Citations = 15

15 inventors:

Cyrille Drouot (9 out of 9 patents)

Thierry Bordet (7 out of 7 patents)

Bruno Buisson (6 out of 6 patents)

4. Rebecca Pruss (5 out of 5 patents)

5. Corinne Chaimbault (3 out of 3 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Trophos. Retrieved from https://idiyas.com/company/trophos

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…